We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
Cap. Flow
+$87.9M
Cap. Flow %
3.75%
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$65.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$38.6M
3
HCA icon
HCA Healthcare
HCA
+$36.9M
4
COR icon
Cencora
COR
+$28.3M
5
DVA icon
DaVita
DVA
+$24M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$67.4M
2
CI icon
Cigna
CI
+$65.2M
3
MRK icon
Merck
MRK
+$47.9M
4
JNJ icon
Johnson & Johnson
JNJ
+$27.9M
5
WTW icon
Willis Towers Watson
WTW
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.66%
2 Financials 1.72%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
76
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$10.6M 0.45%
323,800
– –
CLSD
77
DELISTED
Clearside Biomedical
CLSD
$10.5M 0.45%
65,000
+2,667
+4% +$325K
BMRN icon
78
BioMarin Pharmaceuticals
BMRN
$12.4B
$10.1M 0.43%
125,000
– –
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$10.1M 0.43%
585,500
+160,500
+38% +$3.13M
ADAP
80
DELISTED
Adaptimmune Therapeutics
ADAP
$9.83M 0.42%
875,000
– –
ACRS icon
81
Aclaris Therapeutics
ACRS
$869M
$9.29M 0.4%
530,000
+115,000
+28% +$2.44M
RIGL icon
82
Rigel Pharmaceuticals
RIGL
$750M
$9.12M 0.39%
257,500
+10,000
+4% +$400K
ZGNX
83
DELISTED
Zogenix, Inc.
ZGNX
$9.03M 0.39%
225,500
– –
CO
84
DELISTED
Global Cord Blood Corporation
CO
$8.98M 0.38%
880,000
– –
SRGA
85
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.97M 0.38%
65,000
– –
TVTX icon
86
Travere Therapeutics
TVTX
$5.78B
$8.94M 0.38%
400,000
– –
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.55B
$8.82M 0.38%
173,000
+10,000
+6% +$504K
ZTS icon
88
Zoetis
ZTS
$30B
$8.44M 0.36%
+101,000
New +$7.96M
BHVN
89
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.37M 0.36%
325,000
+81,000
+33% +$2.42M
ACHN
90
DELISTED
Achillion Pharmaceuticals
ACHN
$8.35M 0.36%
2,250,000
– –
ODT
91
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$8.12M 0.35%
383,500
-26,500
-6% -$625K
SAGE
92
DELISTED
Sage Therapeutics
SAGE
$7.89M 0.34%
49,000
+4,000
+9% +$679K
BLUE
93
DELISTED
bluebird bio
BLUE
$7.68M 0.33%
3,474
– –
CHRS icon
94
Coherus Oncology
CHRS
$196M
$7.68M 0.33%
695,000
+65,500
+10% +$717K
SPRO icon
95
Spero Therapeutics
SPRO
$73M
$7.48M 0.32%
525,000
– –
GBT
96
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.25M 0.31%
150,000
– –
MGNX icon
97
MacroGenics
MGNX
$257M
$6.92M 0.3%
275,000
+50,000
+22% +$1.21M
CRVS icon
98
Corvus Pharmaceuticals
CRVS
$1.17B
$6.63M 0.28%
575,000
+152,400
+36% +$1.44M
IMMU
99
DELISTED
Immunomedics Inc
IMMU
$6.58M 0.28%
+450,000
New +$7.35M
NVTA
100
DELISTED
Invitae Corporation
NVTA
$6.57M 0.28%
1,400,000
+94,000
+7% +$671K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
  • Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
  • Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
  • Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
  • Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
  • Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.